Lexaria Bioscience (LEXX) announced that dosing has begun as scheduled in its human study GLP-1-H25-5 that is comparing oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback